Companies › CastleVax
1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NDV-HXP-S-KP.2 Newcastle Disease Virus-based mucosal vaccine expressing SARS-CoV-2 spike protein (KP.2 va | – | Phase 2 | COVID-19 | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07215520 | NDV-HXP-S-KP.2 | Phase 2 | COVID-19 | Infectious disease | Sep 2026 |
No annotated target.
–
Medicago Brii Biosciences Eveliqure Biotechnologies Sanaria SIGA Technologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.